CHICAGO – With immuno-oncology all the rage, especially against melanoma, at the 50th annual meeting of American Society of Clinical Oncology, the pairing of potential new compounds with ipilimumab (Yervoy, Bristol-Myers Squibb Co.) proved a popular ploy.